Mineral And Bone Disorder Treatment Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033 | Pfizer Inc., Merck & Co. Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical Co. Ltd., Eli Lilly And Company,

As per the report, the mineral and bone disorder treatment market size has grown strongly in recent years. It will grow from $3.06 billion in 2023 to $3.3 billion in 2024 at a compound annual growth rate (CAGR) of 8.0%. The mineral and bone disorder treatment market size is expected to see strong growth in the next few years. It will grow to $4.34 billion in 2028 at a compound annual growth rate (CAGR) of 7.1%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=12956&type=smp

Growing Elderly Population Boosts Mineral And Bone Disorder Treatment Market
The increased elderly population is expected to boost the growth of the mineral and bone disorder treatment market going forward. The elderly population is a demographic group defined as individuals who are 65 years old or older. Elderly people experience muscle and bone mass loss, leading to weakness and reduced strength. Mineral and bone treatment can help prevent age-related changes in muscles, bones and joints, strengthen bones and delay the pace of bone loss. For instance, according to a report published by the World Health Organization (WHO), a Switzerland-based intergovernmental organization, by 2030, the number of people aged 60 years or older is expected to increase from 1 billion in 2020 to 1.4 billion and 2.1 billion by 2050. The number of people aged 80 years or older is projected to be three times from 143 million in 2020 to 426 million in 2050. Therefore, the increased elderly population is driving the growth of the mineral and bone disorder treatment market.

Major Companies Focus On New Product Development To Gain A Competitive Edge
Major companies operating in the mineral and bone disorder treatment market are focusing on developing new products and getting them approved to strengthen their position in the market. Drug approval for mineral and bone is increasing due to the aging population and the increasing prevalence of chronic kidney diseases such as TYMLOS (abaloparatide), which contains the active drug abaloparatide, which is a synthetic (lab-made) form of the human parathyroid hormone. For instance, in December 2022, Radius Health Inc., a US-based biopharmaceutical company, received the approval for TYMLOS (abaloparatide), a parathyroid hormone-related peptide [PTHrP(1-34)] analog for the treatment to increase bone density in men with osteoporosis at high risk of fracture. It works as an anabolic agent for the bone by selectively activating the parathyroid hormone 1 receptor (PTH1R) expressed in osteoblasts and osteocytes, leading to increased bone formation and density.

The mineral and bone disorder treatment market covered in this report is segmented -

1) By Treatment: Diet; Nutrition; Medication; Supplements; Dialysis
2) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
3) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=12956&type=discount

Major players in the mineral and bone disorder treatment market are Pfizer Inc., Merck & Co. Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical Co. Ltd., Eli Lilly And Company, Amgen Inc., GlaxoSmithKline PLC, Teva Pharmaceuticals Industries Ltd., Mylan N.V., Daiichi Sankyo Company Limited, Servier Laboratories Pty Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Glenmark Pharmaceuticals Ltd., Alkem Laboratories Ltd., Zydus Cadila Healthcare Ltd., Alembic Pharmaceuticals Limited, Ajanta Pharma Ltd., Abiogen Pharma Spa, Melinta Therapeutics Inc., Intas Pharmaceuticals Ltd., Radius Health Inc., EffRx Pharmaceuticals SA.

Contents of the report:
1. Executive Summary
2. Mineral And Bone Disorder Treatment Market Report Structure
3. Mineral And Bone Disorder Treatment Market Trends And Strategies
4. Mineral And Bone Disorder Treatment Market - Macro Economic Scenario
5. Mineral And Bone Disorder Treatment Market Size And Growth
…..
27. Mineral And Bone Disorder Treatment Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/mineral-and-bone-disorder-treatment-global-market-report

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.